



OMVOH (Mirikizumab) PRESCRIBER ORDER FORM			
FAX COMPLETED FORM, INSURANCE INFORMATION, CLINICAL DOCUMENTATION (LATEST NOTES & LABS) to (757) 466-1128			
□ NEW PATIENT OR			
☐ CHANGE ORDER: Drug Change	Dose Change	Interval Change	
Patient Name:	Phone:		Date of Birth:
Address:			
Allergies:			
_	Weight: □ lk	os □ kg	
CLINICAL INFORMATION			
Primary Diagnosis Description:	<u> </u>		ICD-10 Code:
, , , ,			1-3-2-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-3-
Is this the first dose?			
□ No – date of next dose due:			
Treatments – Tried and Failed:			
□ PPD (negative) – date:	□ Active	ТВ	
TB Status : □ Last chest X-ray – date:	□ Other:		
□ Past positive TB infection,	course taken:		
OMVOH PRESCRIPTION			
OMVOH (MIRIKIZUMAB) refill as directed x 1 year.			
Induction Dose: ☐ Infuse 300mg IV over at least 30 minutes on Weeks 0, 4, and 8.			
Confirm baseline LFTs and Bilirubin prior to administration and every 6 months thereafter.			
· · · · · · · · · · · · · · · · · · ·			
Maintenance Dose: ☐ Give 200mg SC (given as 2 consecutive injections) at week 12, and every 4 weeks after. Review LFTs and bilirubin every 6 months.			
Review LFTs and bilirubin ev	ery 6 months.		
ANCILLARY ORDERS			
Pre - Medication Orders			
□ Acetaminophen 650mg PO 30 min before infusion.			
□ Diphenhydramine 25mg PO/IV 30 min before infusion			
□ Methylprednisolone Succinate 125mg IV push 20 minutes prior to infusion.			
□ Other:			
PRN Hypersensitivity Meds:			
Epinephrine 0.3mg			
Solu-Cortef 100mg			
Solu-Medrol 125mg			
Diphenhydramine 25-50mg			
NS 500 ML (>30kg)			
I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.			
Prescriber Signature: Date:			ate:
PRESCRIBER INFORMATION			
Prescriber Name:	Phone:		Fax:
Address:			NPI:
City, State, Zip:	lated to a pareous be-like It is it is	found to you often appropriate and and	Office Contact:
CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentially could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to who it is addressed and may contain information that is privileged and confidential, the disclosure of which is			
surject, you to perianties described in feeder and rost state laws. Introverview was intended in the use of the person of entire, to which is addressed and may contain minimation that is privileged and commental, the discussive of which is governed by applicable law, if the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of the information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.			